Recent advances in AD therapeutics using antibodies against forms of amyloid-beta (Aß) have shown success in clinical trials (Cummings et al., 2024) and new agents targeting tau are now being tested (Ayalon et al., 2021; Florian et al., 2023; Mummery et al., 2023; Sexton et al., 2022). The gene discussed is MAPT; the disease is Alzheimer disease.